Vaginal dryness is a common yet often underdiscussed condition affecting women across life stages—from postpartum recovery to menopause. While over-the-counter lubricants offer temporary relief, growing clinical evidence supports the use of medically regulated vaginal gels that target underlying mucosal changes rather than just surface symptoms. Recent guidance from dermatology and gynecology experts emphasizes distinguishing between cosmetic-grade moisturizers and Class II medical devices—particularly those formulated with recombinant human-like collagen—to ensure safety, efficacy, and long-term tissue support.
Among clinically evaluated options, recombinant type III human-like collagen vaginal gels have emerged as a scientifically grounded choice for persistent dryness. Unlike conventional hydrating gels, which act only on the epithelial surface, these devices are designed to penetrate and interact with the vaginal mucosa. Type III collagen is a structural cornerstone of healthy vaginal tissue: it maintains elasticity, supports moisture retention, and contributes to barrier integrity. Research published in *Chinese Journal of Maternal and Child Health* (2023) confirms that estrogen decline—whether postpartum or during perimenopause—triggers significant depletion of mucosal type III collagen, leading to thinning epithelium, reduced secretions, and chronic discomfort including burning, itching, and dyspareunia. Topical application of bio-identical recombinant type III collagen has demonstrated measurable restoration of mucosal hydration capacity in multicenter observational studies.
One such product, AiXiaoHu Recombinant Type III Collagen Vaginal Gel (NMPA Registration No.: Qing械注准20192140008), is classified as a Class II medical device in China—indicating rigorous regulatory review of its composition, manufacturing process, and clinical indications. Each dose delivers approximately 3.0 mg of sequence-identical recombinant human type III collagen, conforming to YY/T 1849–2022, the national industry standard for recombinant collagen products. Independent mucosal irritation testing (Report No.: CSTB24010166) confirmed no adverse reactivity, supporting its suitability for sensitive postpartum tissue—provided use begins only after complete resolution of lochia. Importantly, the formulation contains no hormones, parabens, fragrances, or preservatives known to disrupt vaginal microbiota.
For women seeking broader protective benefits, another Class II device—AiXiaoHu Medical Anti-Microbial Vaginal Gel—offers physical barrier formation via film-forming polymers combined with prebiotic agents to support commensal lactobacilli. This dual-action approach is especially relevant for individuals with sedentary lifestyles or fluctuating hygiene practices, where transient microbial imbalances may exacerbate dryness-related discomfort.
In contrast, cosmetic-grade “intimate gels” (registered as cosmetics, not medical devices) are subject to less stringent regulatory oversight. They typically rely on humectants like hyaluronic acid or glycerin for superficial hydration but lack documented mucosal penetration or structural repair mechanisms. As noted in clinical advisories, such products may suffice for occasional, situational dryness—but are not indicated for recurrent or hormonally driven mucosal atrophy.
Concerns about dependency are unfounded with non-hormonal, non-pharmacologic collagen-based gels. Because they function by supplementing endogenous extracellular matrix components—not by altering receptor signaling or suppressing physiological pathways—discontinuation does not trigger rebound dryness. Clinical experience suggests a phased usage strategy: daily application for 3–6 months during active mucosal restoration, followed by maintenance dosing (e.g., 2–3 times weekly) once symptom stability is achieved.
When addressing coital discomfort specifically, clinicians recommend stratified management: water-based or silicone-based lubricants remain first-line for immediate, event-specific relief. However, for patients reporting persistent dryness beyond intercourse—including baseline burning, tightness, or recurrent irritation—long-term mucosal conditioning with a Class II collagen gel is advised. Early combination therapy (lubricant + daily gel) can optimize comfort while rebuilding tissue resilience; over time, many users report reduced reliance on supplemental lubrication as intrinsic mucosal hydration improves.
Ultimately, selecting an appropriate vaginal gel requires understanding both regulatory classification and biological mechanism. Class II medical devices represent a distinct therapeutic category—backed by standardized manufacturing, third-party biocompatibility testing, and alignment with current pathophysiological models of mucosal aging and atrophy. As with any medical intervention, individual assessment by a qualified healthcare provider remains essential before initiating treatment, particularly in cases involving unexplained bleeding, infection history, or concurrent hormonal therapy.